Physician profile
Thomas E Beatrous
NPI 1306853700
$1,715.68
in general payments reported to CMS, 2019-2025
32 companies · $18.68 in 2025
The $18.68 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $546 · 2021: $324 · 2022: $575 · 2023: $39.99 · 2025: $18.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $214.11 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $205.76 | 2019-2022 | |
| Novocure INC. | $111.10 | 2019-2022 | |
| Octapharma USA, INC. | $108.86 | 2020-2022 | |
| Celgene Corporation | $73.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $73.23 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $71.62 | 2020-2022 | |
| Sobi, INC | $71.49 | 2022 | |
| Eisai INC. | $64.48 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $57.63 | 2021 | |
| Janssen Biotech, INC. | $50.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.67 | 2020-2023 | Opdivo |
| Amgen INC. | $47.38 | 2020-2021 | |
| Clovis Oncology, INC. | $47.36 | 2019-2020 | |
| Abbvie INC. | $45.31 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.43 | 2019-2020 | |
| Exelixis INC. | $39.66 | 2020 | |
| Aveo Pharmaceuticals, INC. | $36.94 | 2021-2022 | |
| Pfizer INC. | $36.57 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.57 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $28.81 | 2019 | |
| Dendreon Pharmaceuticals LLC | $26.76 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $24.99 | 2023 | Onivyde, Somatuline Depot |
| Amag Pharmaceuticals, INC. | $23.03 | 2022 | |
| Servier Pharmaceuticals LLC | $22.91 | 2022 | |
| Coherus Oncology, INC. | $18.02 | 2022 | |
| Seagen INC. | $17.15 | 2022 | |
| Acrotech Biopharma INC. | $17.07 | 2021 | |
| Daiichi Sankyo INC. | $15.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2019 | |
| Tersera Therapeutics LLC | $14.52 | 2021 | |
| Puma Biotechnology, INC. | $13.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Beatrous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.